Sign up to all DiabetesontheNet journals
Journals
Sign up to all DiabetesontheNet journals
By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.
Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.
We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.
Diabetes &
Primary Care
Issue:
Vol:23 | No:05
Diabetes Distilled: Clarity and consensus on diabetes remission
Previous definitions of remission differed in different countries, causing confusion about remission diagnosis and ongoing surveillance. An expert panel, representing the Endocrine Society, the European Association for the Study of Diabetes, Diabetes UK and the American Diabetes Association (ADA), has published a consensus report on the definition and interpretation of remission in type 2 diabetes.
Consensus was reached on the following areas:
The authors identified areas requiring further exploration: Should a different HbA1c value or CGM measure be used to define remission, or CGM measures? What is the optimal timing of repeat testing? Are there benefits in continuing metformin? What happens to gut hormones? Is there variation in the duration of remission depending on how it is achieved? And what are the long-term outcomes, including complications, quality of life and function?
Consensus authors’ notes
A consensus report contains a comprehensive examination of a topic by an expert panel and usually includes analysis, evaluation and opinion. A consensus report is needed when clinicians, scientists, regulators and/or policy makers seek guidance and/or clarity on a medical or scientific issue for which the evidence is contradictory, emerging or incomplete. The expert panel can also identify gaps in evidence and propose areas of future research.
This consensus report, published simultaneously in The Journal of Clinical Endocrinology & Metabolism, Diabetologia, Diabetic Medicine and Diabetes Care, reflects the joint working of the expert representatives of the organisations in preparation of the consensus. The authors highlight that it should not be seen as an ADA Position Statement or as a treatment guideline, but rather it proposes definitions and ways to assess glycaemia, and facilitate collection and analysis of data.
To read the report in full, click here.
Riddle MC, Cefalu WT, Evans PH et al (2021) Consensus report: Definition and interpretation of remission in type 2 diabetes. Diabet Med 30 Aug [Epub ahead of print]
Updated guidance from the PCDS and ABCD: Managing the national GLP-1 RA shortage
Diabetes Distilled: Fib-4 – A diagnostic and prognostic marker for liver and cardiovascular events and mortality
At a glance factsheet: Tirzepatide for management of type 2 diabetes
Editorial: Lipid management, tirzepatide and hybrid closed-loop: What does new NICE guidance recommend?
Case report: Pancreatic cancer – assessing diabetes in a thin elderly person
Prescribing pearls: A guide to DPP-4 inhibitors (gliptins)
How to conduct an extended review for people with early-onset type 2 diabetes
Advice on selecting alternative glucose-lowering therapies when GLP-1 RAs used in the management of type 2 diabetes in adults are unavailable.
22 Mar 2024
Should sequential Fib-4 testing now be made part of ongoing care in people with obesity and/or type 2 diabetes?
18 Mar 2024
Indications, benefits and side effects of tirzepatide, plus tips for prescribing.
6 Mar 2024
With a raft of newly published NICE guidance, Jane Diggle discusses the implications for practice in primary care.
6 Mar 2024